Literature DB >> 6871478

Antithrombin III (AT III) Padua2: a "new" congenital abnormality with defective heparin co-factor activities but no thrombotic disease.

A Girolami, F Fabris, G Cappellato, L Sainati, G Boeri.   

Abstract

A "new" antithrombin III (AT III) abnormality is described in five members of the same family. None of the affected members showed thrombotic manifestations and no consanguinity was present in the family. The main laboratory features were: normal routine clotting tests, slightly decreased AT III activities in all assays carried out in the presence of heparin. In the absence of heparin, antithrombin III activities were instead within normal limitis. Progressive AT III activity and AT III antigen were also normal. Crossed immunoelectrophoresis in the absence of heparin showed a normal pattern both in plasma and serum. In the presence of heparin, the propositi's plasma showed a major, less anodal, abnormal peak and a smaller normal peak. Three peaks were present in the propositi's serum as compared with the two normal ones. This AT III abnormality is different from AT III Padua previously described by us and we propose the toponym of Antithrombin Padua-2 to define this condition.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6871478     DOI: 10.1007/bf02482643

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  25 in total

1.  INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.

Authors:  O EGEBERG
Journal:  Thromb Diath Haemorrh       Date:  1965-06-15

2.  Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia.

Authors:  G Sas; G Blaskó; D Bánhegyi; J Jákó; L A Pálos
Journal:  Thromb Diath Haemorrh       Date:  1974-09-30

3.  Prothrombin padua: a "new" congenital dysprothrombinemia.

Authors:  A Girolami; G Bareggi; A Brunetti; A Sticchi
Journal:  J Lab Clin Med       Date:  1974-11

4.  Familial thrombosis due to antithrombin 3 deficiency.

Authors:  E Marciniak; C H Farley; P A DeSimone
Journal:  Blood       Date:  1974-02       Impact factor: 22.113

5.  Quantitative immunoelectrophoresis of human serum proteins.

Authors:  H G Clarke; T Freeman
Journal:  Clin Sci       Date:  1968-10       Impact factor: 6.124

6.  Heparin cofactor activity measured with an amidolytic method.

Authors:  O R Odegard; M Lie; U Abildgaard
Journal:  Thromb Res       Date:  1975-04       Impact factor: 3.944

7.  Abnormal migration of serum antithrombin III in patients on coumarin therapy by cross-immunoelectrophoresis.

Authors:  A Girolami; G M Patrassi; C Vianello; V Pengo
Journal:  Br J Haematol       Date:  1981-11       Impact factor: 6.998

8.  Antifactor Xa activity measured with amidolytic methods.

Authors:  O R Odegård; M Lie; U Abildgaard
Journal:  Haemostasis       Date:  1976

9.  Familial thrombosis: inherited deficiency of antithrombin III.

Authors:  M Mackie; B Bennett; D Ogston; A S Douglas
Journal:  Br Med J       Date:  1978-01-21

10.  The determination of antithrombin III. Comparison of six methods. Effect of oral contraceptive therapy.

Authors:  H Bounameaux; F Duckert; M Walter; Y Bounameaux
Journal:  Thromb Haemost       Date:  1978-06-30       Impact factor: 5.249

View more
  3 in total

1.  Antithrombin III Padua 2: a single base substitution in exon 2 detected with PCR and direct genomic sequencing.

Authors:  R J Olds; D A Lane; R Caso; A Girolami; S L Thein
Journal:  Nucleic Acids Res       Date:  1990-04-11       Impact factor: 16.971

2.  Associated von Willebrand disease as a possible cause of lack of thrombosis in an AT III abnormality (AT III Trento).

Authors:  A Girolami; M G Cappellato; M A Vicarioto; S Casonato; F Marafioti
Journal:  Blut       Date:  1986-01

3.  Investigation of the Differences in Antithrombin to Heparin Binding among Antithrombin Budapest 3, Basel, and Padua Mutations by Biochemical and In Silico Methods.

Authors:  Réka Gindele; Krisztina Pénzes-Daku; Gábor Balogh; Judit Kállai; Réka Bogáti; Bálint Bécsi; Ferenc Erdődi; Éva Katona; Zsuzsanna Bereczky
Journal:  Biomolecules       Date:  2021-04-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.